Table: Santen Pharm -2016/17 group results (IFRS)
10/05/2017 07:00
May 10 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2017 Mar 31, 2016 Mar 31, 2018 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 199.10 195.29 218.00
(+1.9 pct) (+20.7 pct) (+9.5 pct)
Operating 32.48 80.18 37.40
(-59.5 pct) (+126.7 pct) (+15.2 pct)
Pretax 31.82 79.47 37.70
(-60.0 pct) (+121.6 pct) (+18.5 pct)
Net 23.06 53.37 26.90
(-56.8 pct) (+122.1 pct) (+16.6 pct)
EPS Basic 56.20 yen 128.99 yen 66.23 yen
EPS Diluted 55.99 yen 128.41 yen
Ann Div 26.00 yen 25.00 yen 26.00 yen
-Q2 Div 13.00 yen 12.00 yen 13.00 yen
-Q4 Div 13.00 yen 13.00 yen 13.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T
((Tokyo Headline News Desk +813 6441 1812))